title: Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose.
abstract: We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, naïve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Lanzafame
authors.forename: Emanuela
authors.initials: E
authors.lastname: Lattuada
authors.forename: Fabiana
authors.initials: F
authors.lastname: Corsini
authors.forename: Ercole
authors.initials: E
authors.lastname: Concia
authors.forename: Sandro
authors.initials: S
authors.lastname: Vento
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D000069446:Atazanavir Sulfate; D005260:Female; D015658:HIV Infections; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D019562:Viral Load / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate